Extracellular matrix dermatopontin modulates prostate cell growth in vivo

Journal of Endocrinology

Volumn 190, Issue 2, 2006, Pages 351-361

  Takeuchi, Takumi ^a   Suzuki, Motofumi ^a   Kumagai, Jimpei ^a   Kamijo, Toshiyuki ^a   Sakai, Masato ^a   Kitamura, Tadaichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALKALINE PHOSPHATASE; COMPLEMENTARY DNA; DERMATOPONTIN; HYBRID PROTEIN; PROBASIN; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN TARGETING; RAT; STROMA; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; MODELS, ANIMAL; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEOCHONDROITIN SULFATES; RATS; STAINING AND LABELING; TRANSFECTION;

EID: 33747875683     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.1.06619     Document Type: Article

References (27)

1. Catherino WH, Leppert PC, Stenmark MH, Payson M, Potlog-Nahari C, Nieman LK & Segars JH 2004 Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 40 204-217.
2. Diatchenko L, Lau CY, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED et al. 1996 Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. PNAS 93 6025-6030.
3. Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, Millimaggi D & Teti A 1999 Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. International Journal of Cancer 81 395-403.
4. Festuccia C, Angelucci A, Gravina GL, Villanova I, Teti A, Albini A & Bologna M 2000 Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. International Journal of Cancer 85 407-415.
5. Forbes EG, Cronshaw AD, MacBeath JR & Holmes DJ 1994 Tyrosine-rich a cidic matrix protein (TRAMP) is a tyrosine-sulphated and widely distributed protein of the extracellular matrix. FEBS Letters 351 433-436.
6. Hepburn PJ, Griffiths K & Harper ME 1997 Angiogenic factors expressed by human prostatic cell lines: effect on endothelial cell growth in vitro. Prostate 33 123-132.
7. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M & Lee C 1996 Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 56 44-48.
8. Konno-Takahashi N, Takeuchi T, Shimizu T, Nishimatsu H, Fukuhara H, Kamijo T, Moriyama N, Tejima S & Kitamura T 2003 Engineered IGF-I expression induces glandular enlargement in the murine prostate. Journal of Endocrinology 177 389-398.
9. Konno-Takahashi N, Takeuchi T, Nishimatsu H, Kamijo T, Tomita K, Schalken JA, Tejima S & Kitamura T 2004 Engineered FGF-2 expression induces glandular epithelial hyperplasia in the murine prostatic dorsal lobe. European Urology 46 126-132.
10. Kuroda K, Okamoto O & Shinkai H 1999 Dermatopontin expression is decreased in hypertrophic scar and systemic sclerosis skin fibroblasts and is regulated by transforming growth factor-beta1, interleukin-4, and matrix collagen. Journal of Investigative Dermatology 112 706-710.
11. Nakamoto T, Chang CS, Li AK & Chodak GW 1992 Basic fibroblast growth factor in human prostate cancer cells. Cancer Research 52 571-577.
12. Neame PJ, Choi HU & Rosenberg LC 1989 The isolation and primary structure of a 22 kDa extracellular matrix protein from bovine skin. Journal of Biological Chemistry 264 5474-5479.
13. Niwa H, Yamamma K & Miyazaki J 1991 Efficient selection for high-expression transfectant with a novel eukaryotic vector. Gene 108 193-199.
14. Okamoto O, Suzuki Y, Kimura S & Shinkai H 1996 Extracellular matrix 22 kDa protein interacts with decorin core protein and is expressed in cutaneous fibrosis. Journal of Biochemistry (Tokyo) 119 106-114.
15. Okamoto O, Fujiwara S, Abe M & Sato Y 1999 Dermatopontin interacts with transforming growth factor beta and enhances its biological activity. Biochemical Journal 337 537-541.
16. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS et al. 1993 Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Molecular Endocrinology 7 23-36.
17. Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Iozzo RV, Garaci E et al. 2002 Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation. Prostate 53 310-321.
18. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R et al. 2004 Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Research 64 2270-2305.
19. Superti-Furga A, Rocchi M, Schafer BW & Gitzelmann R 1993 Complementary DNA sequence and chromosomal mapping of a human proteoglycan-binding cell-adhesion protein (dermatopontin). Genomics 17 463-467.
20. Takeda U, Utani A, Wu J, Adachi E, Koseki H, Taniguchi M, Matsumoto T, Ohashi T, Sato M & Shinkai H 2002 Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. Journal of Investigative Dermatology 119 678-683.
21. Takemoto S, Murakami T, Kusachi S, Iwabu A, Hirohata S, Nakamura K, Sezaki S, Havashi J, Suezawa C, Ninomiya Y et al. 2002 Increased expression of dermatopontin mRNA in the infarct zone of experimentally induced myocardial infarction in rats: comparison with decorin and type I collagen mRNAs. Basic Research in Cardiology 97 461-468.
22. Takeuchi T, Sasaki Y, Ueki T, Kaziwara T, Moriyama N, Kawabe K & Kakizoe T 1996 Modulation of growth and apoptosis response in PC-3 and LNCAP Prostate-cancer cell lines by Fas. International Journal of Cancer 67 709-714.
23. Takeuchi T, Ueki T, Nishimatsu H, Kajiwara T, Ishida T, Jishage K, Ueda O, Suzuki H, Li B, Moriyama N et al. 1999 Accelerated rejection of Fas-ligand expressing heart grafts. Journal of Immunology 162 518-522.
24. Takeuchi T, Nishimatsu H, Ueki T, Kajiwara T, Fukuhara H, Ishida T, Moriyama N & Kitamura T 2000 Differentially expressed mRNAs in androgen-independent but not androgen-dependent Shionogi carcinoma. Urological Research 28 82-85.
25. Tsibris JC, Segars J, Coppola D, Mane S, Wilbanks GD, O'Brien WF & Spellacy WN 2002 Insights from gene arrays on the development and growth regulation of uterine leiomyomata. Fertility and Sterility 78 114-121.
26. Tzen CY & Huang YW 2004 Cloning of murine early quiescence-1 gene: the murine counterpart of dermatopontin gene can induce and be induced by cell quiescence. Experimental Cell Research 294 30-38.
27. Wilding G, Zugmeier G, Knabbe C, Flanders K & Gelmann E 1989 Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Molecular and Cellular Endocrinololy 62 79-87.